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Family health history (FHH) is a simple and cost-effective clinical tool widely used 
by genetic professionals. Although the value of FHH for assessing personal and familial 
health and reproductive risk within a prenatal population has been demonstrated in past 
studies, its utility within a genetic carrier screening population has not been evaluated. The 
purpose of this study was to examine the utility of FHH as a clinical screening tool and 
explore the general outcomes of full FHH evaluations within an expanded carrier screening 
(ECS) population. A retrospective chart review was conducted for 500 consults, which 
included 3-generation pedigrees, using data from the genetic testing company Recombine. 
Data from the consult letters were examined to assess the incidence of findings that met 
criteria for further action. Findings were assigned to 1 of 2 categories: requiring further 
follow-up, or requiring general risk counseling, which could include risk assessment and/or 
patient education. Analysis was done to examine the types of follow-up recommendations 
that were made and the topics discussed in general risk counseling. Of the 190 consults with 
negative carrier screening results, 117 (23.4% of the total consults) had additional indications 
in the family histories that warranted recommendations for further follow-up, general risk 
counseling, or both. The family history evaluations elicited cancer genetic counseling 
recommendations in 141 consults with either positive or negative carrier screening results, 
which comprised 28.2% of all consults (95% confidence interval of 3.94%). Autoimmune 
and psychiatric disorders were the most frequent topics requiring general risk counseling, 
occurring in 16.8% and 10.0% of all consults (95% confidence interval of 3.28% and 2.62%, 
respectively). These findings demonstrate the high clinical utility of FHH and validate its use 
in healthcare settings. FHH evaluations provide supplemental information to an individual or 
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Family health history (FHH) is an integral part of genetic counseling consultations. 
Collecting FHH in the form of a pedigree often serves as the initial step for a genetic 
evaluation (Bennett, 2012). The pedigree provides a graphic representation of medical-family 
information and biological relationships through standardized nomenclature established by 
the Pedigree Standardization Task Force of the National Society of Genetic Counselors 
(Bennett et al., 1995; Bennett et al., 2008). This allows for an easy and consistent method of 
recording and interpreting family health information. The family pedigree has long been 
recognized as a cost-effective risk assessment tool (Bennett, 2012). It can be used to identify 
at-risk individuals, establish patterns of inheritance, calculate disease risks, and distinguish 
genetic contributions from other risk factors (2012). One of its particular advantages is 
assisting in risk assessment for conditions without a known molecular cause or distinct 
Mendelian inheritance pattern (Brenda J Wilson et al., 2009) 
The scope of a FHH evaluation is often dependent on the practice setting and patient 
population (ACOG, 2011). Each type of evaluation serves its own purpose and offers its own 
advantages. Directed family history evaluations utilize targeted questions for the purpose of 
assessing disease-risk; these types of directed evaluations are typically used in specialties 
such as cancer genetics, neurogenetics, and cardiovascular genetics to capture FHH 
information that is relevant to the condition being assessed (Blankstein & Foody, 2014; Lu et 
al., 2014; Rubinstein et al., 2011). Detailed family history evaluations tend to be broader in 
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scope and are more frequently used in preconception and prenatal care (Farahi & Zolotor, 
2013). A number of professional health organizations, including the Centers for Disease 
Control and Prevention, U.S. Office of the Surgeon General, American Heart Association, 
American College of Obstetrics and Gynecology, and American Society of Clinical 
Oncology, endorse the use of thorough FHH as a risk assessment tool given its many benefits 
(ACOG, 2011; Lu et al., 2014; Tarini & McInerney, 2013; Wu et al., 2015). 
Besides its effectiveness as a risk assessment tool, the utility of FHH as a clinical tool 
is evident by the array of other functions it serves. It is useful for making a diagnosis, guiding 
testing strategies, determining reproductive options, and informing decisions on medical 
management and surveillance (Bennett, 2012). Collecting FHH also presents opportunities 
for rapport building, patient education, and exploration of the patient’s understanding of the 
condition or disease of interest (2012). 
There are significant systemic, clinician, and patient-barriers to FHH that hinder its 
application in clinical practice (Wu et al., 2015). Systemic barriers include limited resources, 
including the time and availability of clinical personnel to obtain a thorough family history 
(2015). Clinician barriers include the availability of licensed and/or certified genetic 
professionals with the knowledge and skills to synthesize and interpret family history data for 
risk stratification (2015). Patient barriers pertain to the inherent limitations of patient-
reported information (2015). A systematic review of the role of family history in risk 
assessment conducted by Wilson et al. found that the absence of disease in relatives is more 
often correctly reported than the presence of disease (Brenda J Wilson et al., 2009). This 
shows that patient-reported family history data has the potential to be inaccurate or incorrect. 
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Inadequate knowledge about FHH presents an additional barrier in the medically underserved 
population (Kaphingst et al., 2012).  
FHH can be made more valuable when used in conjunction with genetic testing; FHH 
provides context for the interpretation of genetic testing results, and risk factors identified 
through FHH evaluation may prompt consideration of more extensive genetic evaluation 
and/or testing (Bennett, 2012). The type of genetic evaluation or testing is often specific to 
the practice setting.  
In reproductive medicine, population-based carrier screening is an integral part of 
genetic testing and is gaining more widespread use as a screening tool (Yao & Goetzinger, 
2016). Historically, the initial aims of genetic carrier screening focused on identifying 
carriers to prevent disease occurrence and reduce disease frequency in successive generations 
(Khoury, McCabe, & McCabe, 2003). In the 1970’s, carrier screening focused on identifying 
carriers of Tay-Sachs disease within the Ashkenazi Jewish population (Beaudet, 2015). Due 
to historical and social factors that limited potential reproductive partners, there was a high 
incidence of Tay-Sachs within this population (Gross, Pletcher, & Monaghan, 2008). With 
the rapid progression of disease-causing genes being identified in other specific populations, 
ethnicity-based carrier screening panels were expanded to include additional diseases, such 
as β-thalassemia, sickle cell anemia, and cystic fibrosis (Beaudet, 2015). By the 2010’s, 
many companies began to offer ‘universal carrier screening,’ as opposed to ethnicity-based 
screening for only the at-risk populations (2015). Screening panels went from testing more 
than 100 genes using SNP-microarray to applying next-generation sequencing to 437 target 
genes (2015). Genetic carrier screening has evolved to encompass autosomal recessive and x-
linked disease causing genetic variants (2015). With the increasing awareness among genetic 
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carrier screening, the American College of Obstetricians and Gynecologists has endorsed the 
use of universal carrier screening in the prenatal and preconception setting (Romero, Rink, 
Biggio, & Saller, 2017). The recent modification was brought about by the growing 
uncertainty of a patient’s entire ethnicity or background (2017). As healthcare providers and 
professional organizations push toward universal testing, the need for patient education about 
the testing received, and risk assessment of the testing results, will increase.  
In the preconception and prenatal care setting, genetic carrier screening is often a 
standard recommendation and is an essential component of predicting risk for inherited 
genetic conditions (Edwards et al., 2015). In this setting, genetic carrier screening is typically 
used in conjunction with FHH to assess an individual's personal and reproductive risk (Farahi 
& Zolotor, 2013; Yao & Goetzinger, 2016). The aim of genetic carrier screening is to 
identify individuals who carry a disease-causing variant that places them at an increased risk 
for having offspring affected with that condition (Beaudet, 2015). This risk is particularly 
significant if the individual’s partner is found to be a carrier of the same condition (2015). 
Genetic carrier screening enables at-risk couples to be informed of the genetic risks to their 
offspring and of the reproductive options available to them (Borry et al., 2011). Genetic 
carrier screening also provides couples with the opportunity to actively engage in managing 
their reproductive risks through preconception planning and the use of in vitro fertilization 
with pre-implantation genetic diagnosis (IVF with PGD) (Edwards et al., 2015). Through 
IVF with PGD, high-risk couples have the option to screen for specific genetic conditions 
prior to transfer of the embryo, greatly reducing their risk of an affected offspring (Antonios, 
2012). Genetic carrier screening also allows for early detection of potentially affected 
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offspring, which may assist in the development of specific management protocols and lead to 
greater preparedness within families (Ross, Ross, Saal, David, & Anderson, 2013). 
Genetic carrier screening and FHH are mutually informative tools for obtaining 
insight into reproductive risk.  While several studies have looked into the utility of directed 
family history as a risk assessment tool for specific diseases, few have examined the overall 
utility of family history as a clinical tool. For the 2009 National Institute of Health State-of-
the-Science conference, the Agency for Healthcare Research and Quality prepared a 
systematic review, which found a dearth of evidence to support the clinical utility of FHH 
(Tarini & McInerney, 2013). The purpose of this study was to examine the general outcomes 
of full family history evaluations in the context of post-expanded carrier screening genetic 
counseling sessions. Further goals of this study were to describe the type of information that 
can be elicited from a FHH evaluation and to evaluate the clinical utility of the information 
elicited. 
 
Materials and Methods 
This study is a retrospective chart review using Recombine’s patient database. 
Recombine is a genetic testing company that provides expanded carrier screening 
(CarrierMap). The CarrierMap panel assesses an individual’s carrier status for approximately 
300 autosomal recessive and x-linked conditions (Appendix A). A randomly selected sample 
of consults from February 1, 2016 to February 29, 2016 was screened for eligibility into the 
study. A total of 500 consults meeting the inclusion criteria were obtained. The inclusion 
criteria included consults in which an individual or a couple received CarrierMap testing, and 
subsequently consented to a full family history evaluation. For the purpose of this study, a 
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full family history evaluation was defined as a three-generation pedigree in which family 
members were assessed for intellectual disabilities, learning disabilities, birth defects, 
blindness, deafness, muscle or skeletal disorders, blood disorders, infant deaths, infertility, 
recurrent pregnancy loss, consanguinity, and known genetic conditions. The consults were 
conducted by twenty-one licensed and/or certified genetic counselors with varying years of 
experience. Data was extracted from the consult letters, and coding was specified for the 
following variables: consult ID, genetic counselor conducting consult, couple or individual 
consult, reported gender, date of birth, ethnicity of each individual, indication for testing, 
carrier screening results, additional follow-up testing based on the carrier screening results, 
FHH findings such as those requiring recommendations for further follow-up or general risk 
counseling, and known genetic conditions in the family. For the analysis, FHH findings were 
assigned to one of two categories: requiring further follow-up, or requiring general risk 
counseling, which could include risk assessment and/or patient education. General risk 
counseling was defined as any discussion on reproductive or recurrence risk based on family 
history and available empiric data. Patient education does not generally include personalized 
risk information, and may be a part of the general risk counseling process, depending on the 
patient’s knowledge and understanding of the condition being discussed. When a patient 
received education, information was discussed about the reported finding or condition, 
including clinical features and patterns of inheritance. Data was de-identified, and no 
identifiable information was stored. Because the data included private health information, it 
was maintained in a password-protected database. Once data extraction was completed, the 
original spreadsheet containing the health privacy information was destroyed. 
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Initial statistical analysis was performed by a statistician at Sarah Lawrence College, 
using statistical software, SPSS. Additionally, an independent data analyst was consulted in 
regards to the confidence interval calculations. Excel was used to calculate the frequency and 
confidence interval based on the sample size and observed sample proportion. A two-way 
frequency table analysis assessed the number of consults in which expanded carrier screening 
yielded positive or negative results with positive or negative FHH findings. The data was 
also analyzed for the number of consults that received a referral or recommendation for 
further follow-up based on the reported family history information and the types of follow-up 
recommendations made. Further analysis was conducted to determine the topics involved 
during general risk counseling. Discussion topics included known genetic disorders, 
psychiatric disorders, and various multifactorial conditions, among others. 
 
Results 
Consults were screened based on the established inclusion criteria. Eight hundred and 
sixteen consults were reviewed, of which 316 (38.7%) consults did not meet the inclusion 
criteria. A total of 500 consults were used in the final analysis. Consults that were excluded 
from the data set were those that received testing other than the CarrierMap screening panel 
through Recombine or declined a full family history evaluation. The consults analyzed 
consisted of 206 (41.2%) couple consults and 294 (58.8%) individual consults (Table 1). The 
sample population was composed of 482 females and 222 males.  
Table 1. Distribution of Consults 
 Number of Consults Proportion of Consults (%) 
Individual 294 58.8 
Couple 206 41.2 
Total 500 100 
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Genetic carrier screening indications included: IVF using sperm or egg donor, frozen 
embryo transfer, infertility evaluation, egg donor screening, egg cryopreservation, and 
reproductive purposes not otherwise specified (Table 2).  
Table 2. Indications for Genetic Carrier Screening (n=500) 
Indication Number of Consults 
Proportion of 
Consults (%) 
Reproductive, not otherwise specified 422 84.4 
IVF using sperm donor 21 4.2 
IVF using egg donor 8 1.6 
IVF using frozen egg 1 0.2 
Infertility evaluation 10 2.0 
Egg donor screening 23 4.6 
Egg cryopreservation 15 3.0 
 
 
Of the 500 total consults, 310 (62.0%) were consults in which the individual or at 
least one partner of a couple was identified to be a carrier for at least one genetic condition, 
and 190 (38.0%) were consults for individuals or couples who did not have a positive result 
on the CarrierMap screening panel (Table 3).  
Table 3. Expanded Carrier Screening Results (n=500) 
 Number of Consults Proportion of Total Consults (%) 
Positive ECS Resulta 310 62.0% 
Negative ECS Resultb 190 38.0% 
aPositive for the individual, or at least one partner (if a couple) 
bNegative for the individual, or both partners (if a couple) 
 
 
Within the 310 consults with positive carrier screening, 211 (68.0%) also had family 
history indications warranting further follow-up, general risk counseling, or both (Table 4). 
Within the 190 consults that received negative results on expanded carrier screening, 117 
(61.6%) had indications warranting further follow-up, general risk counseling, or both (Table 
4).   
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Table 4. Genetic Carrier Screening Results with and without Significant FHH 
Findings (n=500) 
 Significant Findings in Family History 
No Significant Findings 
in Family History 
Positive ECS Resulta 211 99 
Negative ECS Resultb 117 73 
aPositive for the individual, or at least one partner (if a couple) 
bNegative for the individual, or both partners (if a couple) 
 
  
Consults yielded between one and four types of recommendations for follow-up 
evaluation (Table 5). The 95% confidence interval for the proportion of consults to produce 
any type of follow-up evaluation is 44.4% ± 4.4%, or 40.0% to 48.8%. One hundred fifty-
two consults (30.4%) had only one indication to warrant further follow-up. The 95% 
confidence interval for consults with only one indication is 30.4% ± 4.0%, or 26.4% to 
34.4%. Only two consults in the sample, which make up 0.4% of all consults, had a 
maximum number of four follow-up indications. The 95% confidence interval for consults 
that had four indications is 0.4% ± 0.6%, which is not significant by statistical standards for 
the lower limit.  






Total Consults (%) 
95% Confidence 
Interval (%) 
0 278 55.6 4.4 
1 152 30.4 4.0 
2 53 10.6 2.7 
3 15 3.0 1.5 
4 2 0.4 0.6 
 
Based on family history alone, an overall number of 222 (44.4%) consults had a 
family history finding that warranted further follow-up, and received either a referral or 
recommendation for additional evaluation (Table 6). 
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Table 6. Consults with and without Indications for Further Follow-up Based on 
Family History Alone (n=500) 
 Number of Consults 
Proportion of 
Consults (%) 
With indications for further follow-up 222 44.4 
Without indications for further follow-up 278 55.6 
 
Recommendations for further evaluation were made to the following subspecialties: 
cancer genetics, cardiology and cardiovascular genetics, neurogenetics, general genetics 
evaluation, prenatal ultrasound, infertility work-up, ophthalmology, endocrinology, and 
specialists based on known familial conditions (Table 7). The family history evaluations 
elicited cancer genetic counseling recommendations in 141 consults, which comprised of 
28.2% of all consults. The 95% confidence interval for follow-up recommendations to cancer 
genetic counseling is 28.2% ± 3.9%, or 24.3% to 32.1%. 
Table 7. Recommendations for Further Follow-up Evaluation/Testing Based on 
Family History 
Type of Recommendation Number of Consults 




Cancer Genetics 141 28.2 3.9 
Genetics Evaluation 55 11.0 2.7 
Infertility Work-up 41 8.2 2.4 
Neurogenetics 32 6.4 2.1 
Cardiovascular Genetics 16 3.2 1.5 
Prenatal Ultrasound 16 3.2 1.5 
Ophthalmology 3 0.6 0.7 
Other 7 1.4 1.0 
 
 
A total of 233 (46.6%) consults received general risk counseling, which could contain 
additional risk assessment and/or patient education, for various findings within the family 
history (Table 8). Topics that prompted general risk counseling included known genetic 
disorders, psychiatric disorders, autism spectrum disorder, intellectual disability or learning 
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difficulties, seizures or epilepsy, birth defects, recurrent pregnancy loss or miscarriage, 
autoimmune disorders, other multifactorial conditions, and infant deaths. Overall, family 
indications that warranted some form of general risk counseling and patient education were 
observed in 233 consults, which accounted for approximately 46.6% of all consults (Table 8).  
Table 8. Consults With and Without Indications for General Risk Counseling Based 
on Family History Alone (n=500) 
 Number of 
Consults 
Proportion of 
Total Consults (%) 
With indications for general risk counseling 233 46.6 
Without indications for general risk counseling 267 53.4 
 
 
The confidence interval for the proportion of consults that had at least one finding to 
warrant further discussion of reproductive or health risk was 46.6% ± 4.4%, or 42.2% to 
51.0% (Table 9). Approximately 33.4% (±4.1%) and 10.2% (± 2.7%) of all consults had one 
and two indications, respectively, within the family history that warranted additional 
counseling and education.  
Table 9. Distribution of the Number of Topics Discussed for General Risk 
Counseling Per Consult (n=500) 





Total Consults (%) 
95% Confidence 
Interval (%) 
0 267 53.4 4.4 
1 167 33.4 4.1 
2 51 10.2 2.7 
3 12 2.4 1.3 
4 3 0.6 0.7 
 
Of the consults that did receive general risk counseling (n=233), a large proportion 
belonged to those with only one finding in the family history, which was estimated to be 
71.7% with a confidence interval of 5.8%, or 65.9% to 77.5% (Table 10).  
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Table 10. Distribution of the Number of Topics Discussed for General Risk 
Counseling Per Consult for Consults that Received General Risk Counseling (n=233) 








1 167 71.7 5.8 
2 51 21.9 5.3 
3 12 5.2 2.8 
4 3 1.3 1.4 
 
With regards to topics that were elicited during the evaluation, autoimmune disorders 
and psychiatric conditions emerged as the top two categories at 16.8% and 10.0%, 
respectively (Table 11). The confidence interval for autoimmune disorders and psychiatric 
conditions were 3.3% and 2.6%, respectively. Autism spectrum disorders alone accounted for 
1.4% of consults with a confidence interval of 1.0%, which also was the lowest incidence 
category observed. 
Table 11. Family History Findings that Prompted General Risk Counseling 
Type of Discussion Number of Consults 




Autoimmune Disorders 84 16.8 3.3 
Psychiatric Disorders 50 10.0 2.6 
Other/Multifactorial Conditions 39 7.8 2.4 
Diagnosed Genetic Conditions 33 6.6 2.2 
Birth Defects 32 6.4 2.1 
Intellectual Disability/Learning 
Difficulties 31 6.2 2.1 
Epilepsy/Seizures 18 3.6 1.6 
RPL/Infertility/Stillbirth 12 2.4 1.3 
Neurological Disorders 11 2.2 1.3 
Autism Spectrum Disorder 7 1.4 1.0 
 
Overall, 222 consults (44.4% of the total consults) had FHH indications requiring 
further follow-up and 233 (46.6% of the total consults) had FHH indications requiring 
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general risk counseling (Figure 1). Of the 500 total, 127 (25.4%) consults had family history 




The utility of FHH as a clinical tool was examined by reviewing the type of clinical 
data obtained from a full family history evaluation. This included analyzing the frequency 
with which family history evaluations elicited significant findings and characterizing the type 
of findings observed. Of the 816 consults initially reviewed, 500 consults met inclusion 
criteria and were used to assess the clinical utility of family history evaluations. Expanded 
carrier screening yielded positive results in more than half of the consults. For these 
individuals, the results provided additional insight into their reproductive risk and elucidated 
further testing options for the partner, gamete donor, or intended parent(s). Follow-up testing 
options included expanded carrier screening, targeted gene sequencing, or non-genetic 
laboratory testing, such as a complete blood count and quantitative hemoglobin 
electrophoresis.  
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The type of information elicited from the family history evaluation can be 
characterized into two categories: information that prompted recommendation for further 
follow-up and information that prompted general risk counseling, which could include risk 
assessment and patient education. Overall, a quarter of the total consults had findings within 
the family history that warranted both further follow-up and general risk counseling, 
regardless of carrier screening results. Information elicited during these particular consults 
prompted follow-up recommendations and also yielded additional insight into the 
individual’s and/or couple’s reproductive or personal health risk. Of the 310 consults with 
positive carrier screening results, over two-thirds (68.0%) had additional indications in their 
family history that warranted further evaluation, general risk counseling, or both. For these 
individuals and couples, FHH prompted additional considerations to reproductive and 
personal health risks that otherwise were not detected through expanded carrier screening. Of 
the 190 consults with negative carrier screening results, over three-fifths (61.6%) had family 
history indications that warranted further evaluation, general risk counseling, or both.  
Without a family history evaluation, close to one-fifth (23.4%) of the 500 total 
consults with familial findings that affected the individual or couple’s reproductive or 
personal health risk would have been missed. This frequency is comparable to that of 
previously conducted studies which looked at the frequency of family history findings in 
patients without previously identified genetic concerns. A study by Hafen et al. reviewed 
family history data for 700 women and found that a total of 28.4% had some sort of family 
history finding (Hafen et al., 2009). Of the 28.4% of women with family history findings, 
about 19.1% had a family history “positive” for birth defect or genetic condition with a 
minimal/low risk of recurrence, in which additional evaluation/genetic testing during 
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pregnancy was not indicated, while about 9.3% had family histories “significant” for birth 
defect or genetic condition with an increased risk of recurrence, in which additional 
evaluation/genetic testing during the pregnancy was indicated. Additional studies looking at 
women who were referred for amniocentesis found the frequency of significant family 
history findings to be around 10 to 43% (Cohn et al., 1999; Holzgreve et al., 1983; Langer 
and Kudart, 1990; Meschede et al., 2000; Rubin et al., 1983). The frequency of 23.4% 
ascertained in this study falls within with the range observed in these previously conducted 
studies and is lower than that of Hafen’s study. The differences in the frequencies can be 
accounted for by the parameters used to determine and categorize the significance of family 
history data as well as the demographics of the population sampled. These factors limit the 
extent to which the findings can be generalizable to other prenatal patient populations since 
this study’s cohort was ascertained specifically from a population for which carrier screening 
was indicated. 
FHH, when considered alone, yielded clinically actionable data which prompted 
follow-up recommendations in 222 consults (44.4% of the total consults). This included 
recommendations for follow-up with cancer genetic counseling, cardiology and 
cardiovascular genetics, neurogenetics, a general genetics evaluation, a prenatal ultrasound, 
an infertility work-up, and other subspecialties including ophthalmology, audiology, 
dermatology, and endocrinology. The results of the study indicated that family history 
evaluations were most likely to identify to cancer indications, which produced follow-up 
recommendations for cancer genetic counseling in over a quarter of the total number of 
consults. The second highest number of recommendations made was to a general genetics 
provider; this composed over 10% of total consults. An overwhelming majority of these 
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genetic evaluation recommendations were due to a diagnosis of an autism spectrum disorder 
(ASD) within the family. It was observed that the option of an ASD evaluation to identify the 
underlying cause was dependent on the discretion of the genetic counselor conducting the 
session, as some counselors were more likely to refer, irrespective of the degree of relation to 
the individual or couple.  
Oftentimes, a family history evaluation led to multiple follow-up recommendations; it 
was observed that each consult yielded follow-up recommendations for between one to four 
different types of evaluations. Almost one-third of all consults had one recommendation for 
an additional evaluation. Four recommendations were warranted in two of the 500 consults 
(less than half of one percent). With only two observed in a sample size of 500, consults with 
four different recommendations yielded an insignificant lower confidence bound.  
Some consults had family-history-based findings that elicited discussions on general 
risk counseling. For these particular consults, genetic counselors provided risk assessment 
and patient education as needed. Topics that came up per patient report included known 
genetic disorders within the family, psychiatric disorders, autism spectrum disorders, 
intellectual disability or learning difficulties, seizures or epilepsy, birth defects, recurrent 
pregnancy loss or stillbirth, autoimmune disorders, and other findings including additional 
multifactorial conditions and infant deaths. In close to half of the total consults, general risk 
counseling was provided, which added additional perspective to the reproductive or personal 
health risk information for the individual or couple. General risk counseling occurred most 
frequently for autoimmune disorders, which was discussed in 16.8% of the consults. Some of 
the major disorders most frequently discussed were diabetes, lupus, thyroid disorders, and 
multiple sclerosis. These results have implications for genetic counseling practices, 
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particularly with regards to patient education. Such FHH findings provide opportunities for 
patient education by prompting discussion of co-genetic susceptibility. Psychiatric disorders 
prompted general risk counseling in approximately 10% of all consults, emerging as the 
second most frequently discussed topic. The most frequently discussed psychiatric disorders 
included depression, bipolar disorder, and schizophrenia. A positive family history is the 
greatest recognized risk factor for developing conditions such as schizophrenia and major 
depression (Laursen et al., 2005; Austin and Peay, 2006). Although predictive genetic testing 
is currently not available for these conditions, the relevance of genetic counseling is not 
limited by the absence of testing (Jenkins & Arribas-Ayllon, 2016). Past studies have found 
that providing patient education about etiology offer many benefits to affected individuals 
and their families (Austin & Honer, 2008; Hippman et al., 2013, 2016). Patient education 
serves to improve knowledge, alleviate anxiety, and increase risk perception accuracy in 
those with heightened concern about their risk to develop a mental illness (2008; 2013; 
2016). The frequency with which psychiatric conditions came up in this study highlights the 
value of genetic counseling for individuals with positive family histories, who may benefit 
from patient education and counseling. For this study, general risk counseling for ASD was 
also provided in a little over 1% of all consults; a recurrence risk score was given as part of 
general risk counseling and was calculated based on the degree of relation of the family 
member affected with ASD. For these particular consults with positive family histories for 
ASD, it was determined that a recommendation for a genetics evaluation was not necessary 
but a discussion of reproductive risk was still warranted. Whether a family finding of ASD 
prompted a recommendation for further follow-up or general risk counseling was made at the 
genetic counselor’s discretion. For all of these cases discussed, additional information and 
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insight were gained through general risk counseling and patient education; however, this 
information did not prompt further actions or evaluations for the individual or couple. 
The results of this study are subject to inherent limitations of the data. The inclusion 
criteria for the study restricted the population sample to individuals and couples that received 
expanded carrier screening through Recombine, thereby limiting the overall diversity of the 
patient population. Therefore, these results may only be applicable to genetic counseling 
consults that occur in context of an expanded carrier screening setting. Reported information 
was also subject to the genetic counselor’s assessment of its importance and relevance to the 
consult. The information available through each consult’s chart notes and consult letter may 
not reflect all the details of the consult. This limitation is compounded by the influence of 
counselor differences such as style, technique, and experience, all of which contribute to the 
specific information collected or recorded during a consult. For example, in some cases, 
recommendations were included in the consult letter irrespective of the finding’s actual level 
of significance, relative reproductive risk to the individual or couple, or level of patient 
concern. Counselor discretion also played a role in whether a family history finding yielded a 
recommendation for follow-up or general risk counseling. Specific cases of this were 
observed in cases that involved recurrent pregnancy loss and autism spectrum disorder 
findings. 
Only a small body of research exists on the clinical utility of FHH evaluations. 
Overall, the results of this study provide insights into the type of information that can be 
elicited through a FHH evaluation. FHH provides supplemental information to the individual 
or couple’s expanded carrier screening results, which adds to knowledge of personal health 
risk and reproductive risk. The frequency with which relevant findings were elicited during a 
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family history evaluation also offers further support to its utility as a clinical tool in the 
patient-care setting. Family history studies can serve as a useful evaluation tool for non-
routine screening procedures, diagnostic testing, and referral to genetic counseling in 
different disciplines  (Beadles et al., 2014). Furthermore, FHH can be used as a screening 
tool to identify individuals who would benefit from further evaluation, additional risk 
counseling, or patient education. The results of this study provide support to the broader 
adoption of FHH evaluations in routine clinical care, which further warrants the use of 
genetic counselors in healthcare environments outside of traditional genetic settings (Wilson 
et al., 2012). The implementation of thorough FHH as a routine clinical tool would enable 
better care and risk management for patients and their families (Brock et al., 2010; Tarini & 
McInerney, 2013; Wu et al., 2015). FHH, however, remains an underutilized tool for risk 
assessment in primary care settings (Langlands, Prentice, & Ravine, 2010; Powell et al., 
2013; Tarini & McInerney, 2013). A number of studies have found that FHH data collected 
in primary care settings lacks the completeness needed to be used effectively as a risk 
assessment tool (Powell et al., 2013; Tarini & McInerney, 2013; B. J. Wilson et al., 2012). 
This further emphasizes the need for genetic counseling and genetics consultations to be 
performed by certified genetic professionals. Correct interpretation of FHH requires in-depth 
genetics knowledge that ensures accurate risk assessments, proper risk counseling, and 
appropriate recommendations for follow-up. 
The study also provides perspective on patient’s understanding and knowledge of 
their own FHH as well as insight into health topics that were of highest patient concern. 
Further studies should look into how patients can prepare for a genetics consultation in order 
to obtain the most optimal outcome. A patient’s knowledge of relevant FHH information 
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better enables healthcare professionals to personalize the care plan and management to a 
patient’s risks and needs. From a provider’s perspective, the results of this study elucidated 
on health topics and conditions that tend to come up more frequently than others during a 
FHH evaluation. This may then provide insight into the type of topics that can be expected to 
come up during a genetics consultation. Awareness and knowledge of these topics may be 
beneficial to genetic professionals as this can help facilitate risk assessment and counseling. 
As medicine moves away from the “one size fits all model”, the critical role of FHH in 
personalized medicine has become more apparent than ever. FHH is an easy and simple tool 
with high clinical utility that warrants its adoption into a variety of routine healthcare 
settings. 
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Appendix A: List of Diseases Included on CarrierMap Testing 
 
Disease Name 
11-Beta-Hydroxylase-Deficient Congenital Adrenal Hyperplasia 
17-Alpha-Hydroxylase Deficiency 
17-Beta-Hydroxysteroid Dehydrogenase Deficiency 
21-Hydroxylase-Deficient Classical Congenital Adrenal Hyperplasia 
21-Hydroxylase-Deficient Nonclassical Congenital Adrenal Hyperplasia 
3-Beta-Hydroxysteroid Dehydrogenase Deficiency 
3-Methylcrotonyl-CoA Carboxylase Deficiency: MCCA Related 
3-Methylcrotonyl-CoA Carboxylase Deficiency: MCCB Related 
3-Methylglutaconic Aciduria: Type 3 
3-Phosphoglycerate Dehydrogenase Deficiency 
5-Alpha Reductase Deficiency 




Acute Infantile Liver Failure: TRMU Related 
Acyl-CoA Oxidase I Deficiency 






Alport Syndrome: COL4A3 Related 
Alport Syndrome: COL4A4 Related 
Alport Syndrome: X-linked 
Amegakaryocytic Thrombocytopenia 
Andermann Syndrome 
Androgen Insensitivity Syndrome: Complete 
Antley-Bixler Syndrome 
Argininemia 
Argininosuccinate Lyase Deficiency 
Aromatase Deficiency 
Arthrogryposis, Mental Retardation, & Seizures 
Arts Syndrome 
Asparagine Synthetase Deficiency 
Aspartylglycosaminuria 
Ataxia with Vitamin E Deficiency 





Autosomal Recessive Polycystic Kidney Disease 
Bardet-Biedl Syndrome: BBS1 Related 
Bardet-Biedl Syndrome: BBS10 Related 
Bardet-Biedl Syndrome: BBS11 Related 
Bardet-Biedl Syndrome: BBS12 Related 
Bardet-Biedl Syndrome: BBS2 Related 
Bare Lymphocyte Syndrome: Type II 







Carnitine Palmitoyltransferase IA Deficiency 
Carnitine Palmitoyltransferase II Deficiency 




Charcot-Marie-Tooth Disease with Deafness: X-Linked: GJB1 Related 
Charcot-Marie-Tooth Disease with Deafness: X-Linked: PRPS1 Related 
Chediak-Higashi Syndrome 
Cholesteryl Ester Storage Disease 
Choreoacanthocytosis 
Choroideremia 
Chronic Granulomatous Disease: CYBA Related 
Chronic Granulomatous Disease: X-Linked 
Citrin Deficiency 
Citrullinemia: Type I 
Classical Galactosemia 
Cockayne Syndrome: Type A 
Cockayne Syndrome: Type B 
Cohen Syndrome 
Combined Pituitary Hormone Deficiency: PROP1 Related 
Congenital Disorder of Glycosylation: Type 1A: PMM2 Related 
Congenital Disorder of Glycosylation: Type 1B: MPI Related 
Congenital Disorder of Glycosylation: Type 1C: ALG6 Related 




Congenital Ichthyosis: ABCA12 Related 
Congenital Insensitivity to Pain with Anhidrosis 
Congenital Lipoid Adrenal Hyperplasia 
Congenital Myasthenic Syndrome: CHRNE Related 
Congenital Myasthenic Syndrome: DOK7 Related 
Congenital Myasthenic Syndrome: RAPSN Related 
Congenital Neutropenia: Recessive 
Copper Transport Disorders 
Corneal Dystrophy and Perceptive Deafness 




Cystinuria: Non-Type I 
Cystinuria: Type I 
D-Bifunctional Protein Deficiency 
DMD-Related Muscular Dystrophies 
Diabetes: Recessive Permanent Neonatal 
Du Pan Syndrome 
Dyskeratosis Congenita: RTEL1 Related 
Dystrophic Epidermolysis Bullosa: Recessive 
Ehlers-Danlos Syndrome: Type VIIC 
Ellis-van Creveld Syndrome: EVC Related 
Ellis-van Creveld Syndrome: EVC2 Related 




Factor IX Deficiency 
Factor VIII Deficiency 
Familial Chloride Diarrhea 
Familial Dysautonomia 
Familial Hyperinsulinism: Type 1: ABCC8 Related 
Familial Hyperinsulinism: Type 2: KCNJ11 Related 
Familial Mediterranean Fever 
Fanconi Anemia: Type A 
Fanconi Anemia: Type C 
Fanconi Anemia: Type G 
Fanconi Anemia: Type J 











Globoid Cell Leukodystrophy 
Glucose-6-Phosphate Dehydrogenase Deficiency 
Glutaric Acidemia: Type I 
Glutaric Acidemia: Type IIA 
Glutaric Acidemia: Type IIB 
Glutaric Acidemia: Type IIC 
Glycine Encephalopathy: AMT Related 
Glycine Encephalopathy: GLDC Related 
Glycogen Storage Disease: Type IA 
Glycogen Storage Disease: Type IB 
Glycogen Storage Disease: Type II 
Glycogen Storage Disease: Type III 
Glycogen Storage Disease: Type IV 
Glycogen Storage Disease: Type V 
Glycogen Storage Disease: Type VII 
Guanidinoacetate Methyltransferase Deficiency 
HMG-CoA Lyase Deficiency 
Hemochromatosis: Type 2A: HFE2 Related 
Hemochromatosis: Type 3: TFR2 Related 
Hemoglobinopathy: Hb C 
Hemoglobinopathy: Hb D 
Hemoglobinopathy: Hb E 
Hemoglobinopathy: Hb O 
Hereditary Fructose Intolerance 
Hereditary Spastic Paraplegia: TECPR2 Related 
Herlitz Junctional Epidermolysis Bullosa: LAMA3 Related 
Herlitz Junctional Epidermolysis Bullosa: LAMB3 Related 
Herlitz Junctional Epidermolysis Bullosa: LAMC2 Related 
Hermansky-Pudlak Syndrome: Type 1 
Hermansky-Pudlak Syndrome: Type 3 
Hermansky-Pudlak Syndrome: Type 4 
Holocarboxylase Synthetase Deficiency 




Homocystinuria Caused by CBS Deficiency 
Hunter Syndrome 
Hurler Syndrome 
Hypohidrotic Ectodermal Dysplasia: X-Linked 
Hypophosphatasia 
Inclusion Body Myopathy: Type 2 
Infantile Cerebral and Cerebellar Atrophy 
Isolated Microphthalmia: VSX2 Related 
Isovaleric Acidemia 
Joubert Syndrome 
Juvenile Retinoschisis: X-Linked 
Lamellar Ichthyosis: Type 1 
Laryngoonychocutaneous Syndrome 
Leber Congenital Amaurosis: CEP290 Related 
Leber Congenital Amaurosis: GUCY2D Related 
Leber Congenital Amaurosis: LCA5 Related 
Leber Congenital Amaurosis: RDH12 Related 
Leigh Syndrome: French-Canadian 
Leukoencephalopathy with Vanishing White Matter: EIF2B5 Related 
Leydig Cell Hypoplasia (Luteinizing Hormone Resistance) 
Limb-Girdle Muscular Dystrophy: Type 2A 
Limb-Girdle Muscular Dystrophy: Type 2B 
Limb-Girdle Muscular Dystrophy: Type 2C 
Limb-Girdle Muscular Dystrophy: Type 2D 
Limb-Girdle Muscular Dystrophy: Type 2E 
Limb-Girdle Muscular Dystrophy: Type 2F 
Limb-Girdle Muscular Dystrophy: Type 2I 
Lipoprotein Lipase Deficiency 
Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency 
Lowe Oculocerebrorenal Syndrome 
Lysinuric Protein Intolerance 
MTHFR Deficiency: Severe 
Malonyl-CoA Decarboxylase Deficiency 
Maple Syrup Urine Disease: Type 1A 
Maple Syrup Urine Disease: Type 1B 
Maple Syrup Urine Disease: Type 2 
Maple Syrup Urine Disease: Type 3 
Maroteaux-Lamy Syndrome 
Meckel Syndrome: Type 1 




Medium-Chain Acyl-CoA Dehydrogenase Deficiency 
Megalencephalic Leukoencephalopathy 
Metachromatic Leukodystrophy 
Methylmalonic Acidemia: MMAA Related 
Methylmalonic Acidemia: MMAB Related 
Methylmalonic Acidemia: MUT Related 
Methylmalonic Aciduria and Homocystinuria: Type cblC 
Mitochondrial Complex I Deficiency: NDUFS6 Related 
Mitochondrial DNA Depletion Syndrome: MNGIE Type 
Mitochondrial Myopathy and Sideroblastic Anemia 
Mitochondrial Trifunctional Protein Deficiency: HADHB Related 
Morquio Syndrome: Type A 
Morquio Syndrome: Type B 
Mucolipidosis: Type II/III  
Mucolipidosis: Type IV 
Multiple Pterygium Syndrome 
Multiple Sulfatase Deficiency 
Muscle-Eye-Brain Disease 
Myotubular Myopathy: X-Linked 
Navajo Neurohepatopathy 
Nemaline Myopathy: NEB Related 
Nephrotic Syndrome: Type 1 
Nephrotic Syndrome: Type 2 
Neuronal Ceroid-Lipofuscinosis: CLN5 Related 
Neuronal Ceroid-Lipofuscinosis: CLN6 Related 
Neuronal Ceroid-Lipofuscinosis: CLN8 Related 
Neuronal Ceroid-Lipofuscinosis: MFSD8 Related 
Neuronal Ceroid-Lipofuscinosis: PPT1 Related 
Neuronal Ceroid-Lipofuscinosis: TPP1 Related 
Niemann-Pick Disease: Type A 
Niemann-Pick Disease: Type B 
Niemann-Pick Disease: Type C1 
Niemann-Pick Disease: Type C2 
Nijmegen Breakage Syndrome 
Nonsyndromic Hearing Loss and Deafness: GJB2 Related 
Nonsyndromic Hearing Loss and Deafness: LOXHD1 Related 
Nonsyndromic Hearing Loss and Deafness: MYO15A Related 
Oculocutaneous Albinism: Type 1 
Oculocutaneous Albinism: Type 3 




Oculocutaneous Albinism: Type 4 
Omenn Syndrome: DCLRE1C Related 
Omenn Syndrome: RAG2 Related 
Ornithine Transcarbamylase Deficiency 
Ornithine Translocase Deficiency 
Osteopetrosis: TCIRG1 Related 
POLG Related Disorders: Autosomal Recessive 
Papillon-Lefevre Syndrome 
Pendred Syndrome 
Persistent Mullerian Duct Syndrome: Type I 
Persistent Mullerian Duct Syndrome: Type II 
Phenylalanine Hydroxylase Deficiency 
Polyglandular Autoimmune Syndrome: Type I 
Pontocerebellar Hypoplasia: EXOSC3 Related 
Pontocerebellar Hypoplasia: RARS2 Related 
Pontocerebellar Hypoplasia: SEPSECS Related 
Pontocerebellar Hypoplasia: TSEN54 Related 
Pontocerebellar Hypoplasia: VPS53 Related 
Pontocerebellar Hypoplasia: VRK1 Related 
Primary Carnitine Deficiency 
Primary Ciliary Dyskinesia: DNAI1 Related 
Primary Ciliary Dyskinesia: DNAI2 Related 
Primary Congenital Glaucoma 
Primary Hyperoxaluria: Type 1 
Primary Hyperoxaluria: Type 2 
Primary Hyperoxaluria: Type 3 
Progressive Familial Intrahepatic Cholestasis: Type 2 
Propionic Acidemia: PCCA Related 
Propionic Acidemia: PCCB Related 
Pseudocholinesterase Deficiency 
Pycnodysostosis 
Pyruvate Carboxylase Deficiency 
Pyruvate Dehydrogenase Deficiency 
Pyruvate Dehydrogenase Deficiency: X-Linked 
Renal Tubular Acidosis and Deafness 
Retinal Dystrophies: RLBP1 Related 
Retinal Dystrophies: RPE65 Related 
Retinitis Pigmentosa: CERKL Related 
Retinitis Pigmentosa: DHDDS Related 




Retinitis Pigmentosa: FAM161A Related 




Sanfilippo Syndrome: Type A 
Sanfilippo Syndrome: Type B 
Sanfilippo Syndrome: Type C 
Sanfilippo Syndrome: Type D 





Spinal Muscular Atrophy: SMN1 Linked 
Stargardt Disease 
Stuve-Wiedemann Syndrome 
Sulfate Transporter-Related Osteochondrodysplasia 
Tay-Sachs Disease 
Trichohepatoenteric Syndrome: Type 1 
Tyrosine Hydroxylase Deficiency 
Tyrosinemia: Type I 
Tyrosinemia: Type II 
Usher Syndrome: Type 1B 
Usher Syndrome: Type 1C 
Usher Syndrome: Type 1D 
Usher Syndrome: Type 1F 
Usher Syndrome: Type 2A 
Usher Syndrome: Type 3 







Xeroderma Pigmentosum: Group A 
Xeroderma Pigmentosum: Group C 
Zellweger Spectrum Disorders: PEX1 Related 




Zellweger Spectrum Disorders: PEX10 Related 
Zellweger Spectrum Disorders: PEX2 Related 
Zellweger Spectrum Disorders: PEX6 Related 
 
 
